A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix

R. E. Coleman, J. M. Clarke, M. L. Slevin, J. Sweetenham, C. J. Williams, P. Blake, F. Calman, E. Wiltshaw, P. G. Harper

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

A total of 44 women received a combination of ifosfamide (1.5 g/m2 daily x5) and cisplatin (50 mg/m2 on day 1 only) as first-line chemotherapy for recurrent or metastatic carcinoma of the cervix. In all, 12/42 (38%) evaluable patients responded, with the median duration of response being 7 months. Bone marrow and gastrointestinal toxicity were frequently severe. There were 3 septic death. Although cisplatin plus ifosfamide is an active combination against this disease, these results suggest that it is no more so than either drug used alone.

Original languageEnglish (US)
Pages (from-to)52-54
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume27
Issue number1
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Ifosfamide
Chemotherapy
Cervix Uteri
Cisplatin
Carcinoma
Drug Therapy
Toxicity
Bone
Bone Marrow
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix. / Coleman, R. E.; Clarke, J. M.; Slevin, M. L.; Sweetenham, J.; Williams, C. J.; Blake, P.; Calman, F.; Wiltshaw, E.; Harper, P. G.

In: Cancer Chemotherapy and Pharmacology, Vol. 27, No. 1, 01.01.1990, p. 52-54.

Research output: Contribution to journalArticle

Coleman, RE, Clarke, JM, Slevin, ML, Sweetenham, J, Williams, CJ, Blake, P, Calman, F, Wiltshaw, E & Harper, PG 1990, 'A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix', Cancer Chemotherapy and Pharmacology, vol. 27, no. 1, pp. 52-54. https://doi.org/10.1007/BF00689276
Coleman, R. E. ; Clarke, J. M. ; Slevin, M. L. ; Sweetenham, J. ; Williams, C. J. ; Blake, P. ; Calman, F. ; Wiltshaw, E. ; Harper, P. G. / A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix. In: Cancer Chemotherapy and Pharmacology. 1990 ; Vol. 27, No. 1. pp. 52-54.
@article{a709002cdd6f4afab8c5426a0806d7d7,
title = "A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix",
abstract = "A total of 44 women received a combination of ifosfamide (1.5 g/m2 daily x5) and cisplatin (50 mg/m2 on day 1 only) as first-line chemotherapy for recurrent or metastatic carcinoma of the cervix. In all, 12/42 (38{\%}) evaluable patients responded, with the median duration of response being 7 months. Bone marrow and gastrointestinal toxicity were frequently severe. There were 3 septic death. Although cisplatin plus ifosfamide is an active combination against this disease, these results suggest that it is no more so than either drug used alone.",
author = "Coleman, {R. E.} and Clarke, {J. M.} and Slevin, {M. L.} and J. Sweetenham and Williams, {C. J.} and P. Blake and F. Calman and E. Wiltshaw and Harper, {P. G.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1007/BF00689276",
language = "English (US)",
volume = "27",
pages = "52--54",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix

AU - Coleman, R. E.

AU - Clarke, J. M.

AU - Slevin, M. L.

AU - Sweetenham, J.

AU - Williams, C. J.

AU - Blake, P.

AU - Calman, F.

AU - Wiltshaw, E.

AU - Harper, P. G.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - A total of 44 women received a combination of ifosfamide (1.5 g/m2 daily x5) and cisplatin (50 mg/m2 on day 1 only) as first-line chemotherapy for recurrent or metastatic carcinoma of the cervix. In all, 12/42 (38%) evaluable patients responded, with the median duration of response being 7 months. Bone marrow and gastrointestinal toxicity were frequently severe. There were 3 septic death. Although cisplatin plus ifosfamide is an active combination against this disease, these results suggest that it is no more so than either drug used alone.

AB - A total of 44 women received a combination of ifosfamide (1.5 g/m2 daily x5) and cisplatin (50 mg/m2 on day 1 only) as first-line chemotherapy for recurrent or metastatic carcinoma of the cervix. In all, 12/42 (38%) evaluable patients responded, with the median duration of response being 7 months. Bone marrow and gastrointestinal toxicity were frequently severe. There were 3 septic death. Although cisplatin plus ifosfamide is an active combination against this disease, these results suggest that it is no more so than either drug used alone.

UR - http://www.scopus.com/inward/record.url?scp=0025614853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025614853&partnerID=8YFLogxK

U2 - 10.1007/BF00689276

DO - 10.1007/BF00689276

M3 - Article

C2 - 2245492

AN - SCOPUS:0025614853

VL - 27

SP - 52

EP - 54

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -